AB122 + TAS-120 + nab-paclitaxel + gemcitabine

This drug regimen is a combination therapy composed of four agents: **AB122** (a fully human monoclonal antibody that acts as an anti-PD-1 immune checkpoint inhibitor developed by Arcus Biosciences), **TAS-120** (futibatinib, an irreversible FGFR inhibitor used in targeted cancer therapy), **nab-paclitaxel** (nanoparticle albumin-bound paclitaxel, a microtubule inhibitor chemotherapy formulated for improved delivery), and **gemcitabine** (a nucleoside analog chemotherapy agent with antimetabolite activity). The combination is used in investigational settings, primarily for advanced or metastatic solid tumors, including pancreatic and potentially other cancers. The regimen aims to combine immunotherapy, targeted therapy, and cytotoxic chemotherapy for synergistic antitumor response.

Other names

futibatinibnab-paclitaxelgemcitabinepaclitaxel albumin-bound